Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.
Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.
复制标题
Avelumab（MSB0010718C；抗 PD-L1）与阿西替尼联合作为晚期肾细胞癌患者的一线治疗。
DOI：
--
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
T. Choueiri
中科院分区：
文献类型：
--
作者：
J. Larkin;M. Gordon;F. Thistlethwaite;P. Nathan;B. Rini;M. Martignoni;M. Shnaidman;C. Chiruzzi;A. D. Pietro;T. Choueiri
TPS 4580背景：靶向药物改善了晚期肾细胞癌（aRCC）的结局，但患者（pts）不可避免地产生耐药性。程序性死亡-1受体配体（PD-L1）是重新激活针对多种癌症（包括RCC）的免疫应答的关键治疗靶点。Avelumab* 是一种全人源IgG 1抗PD-L1抗体，在多种肿瘤类型中显示出临床活性。阿昔替尼是一种受体酪氨酸激酶抑制剂（TKI），适用于治疗既往全身治疗失败后的aRCC;阿昔替尼也显示出一线（1 L）治疗的临床活性。在最近的试验中，抗PD-1/TKI组合在aRCC中显示出有希望的临床疗效，初步数据表明与阿昔替尼组合的耐受性更好。这项开放标签、多中心、剂量探索研究（NCT 02493751）评估了avelumab +阿西替尼的新型组合作为aRCC患者的1 L治疗。方法：这项全球Ib期研究的主要目的是评估安全性和...
TPS4580Background: Targeted agents have improved outcomes in advanced renal cell carcinoma (aRCC), but patients (pts) inevitably develop resistance. Programmed death-1 receptor ligand (PD-L1) is a key therapeutic target in the reactivation of the immune response against multiple cancers, including RCC. Avelumab* is a fully human IgG1 anti-PD-L1 antibody showing clinical activity in several tumor types. Axitinib is a receptor tyrosine kinase inhibitor (TKI) indicated for treatment of aRCC after failure of one prior systemic therapy; axitinib also shows clinical activity as a first-line (1L) therapy. In recent trials, anti-PD-1/TKI combinations have shown promising clinical efficacy in aRCC, and preliminary data suggest better tolerability for the combination with axitinib. This open-label, multicenter, dose-finding study (NCT02493751) evaluates the novel combination of avelumab + axitinib as 1L therapy in pts with aRCC. Methods: The primary objective for this global phase Ib study is to assess safety and t...